NASDAQ
VCEL
Last Price
US $46.09
KEY FIGURES
MKT CAP
$2.4B
EPS
TTM
$0.42
PEG
TTM
0.16x
P/E
TTM
109.04x
P/S
TTM
8.01x
YIELD
0.00%
GROWTH
Revenue Y/Y
17.34%
(FY vs FY)
EBITDA Y/Y
Cash Flow (DCF)
Fair Value
Market $46.09
-81.19%
Default assumptions
EBITDA Multiple
Fair Value
Market $46.09
-90.89%
Default assumptions
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Vericel Corporation cash flow to debt ratio of 52.83% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Financial stability - Healthy cash flow growth.
Vericel Corporation's free cash flow has increased -525.88% from $-5.81M last year to $24.75M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Vericel Corporation's debt to equity ratio is 0.27, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Vericel Corporation's debt has decreased relative to shareholder equity from 0.34 last year to 0.27 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Vericel Corporation has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Vericel Corporation earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
Vericel Corporation's profit margin has increased (68.22%) in the last year from 4.37% to 7.35%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Vericel Corporation's short-term assets of $247.44M exceed its short-term liabilities of $49.15M
Decreasing performance - ROA.
Vericel Corporation's return on assets of 4.42% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Vericel Corporation's return on equity of 6.41%, is lower than 15.00%, indicating bad performance
Increasing performance - Earnings quality.
Vericel Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Decreasing performance - Earnings stability.
Vericel Corporation had positive net income in only 2.00 out of 5 years, indicating unstable earnings
Increasing performance - Free cash flow.
Vericel Corporation has positive free cash flow, indicating the company generates cash after capital expenditures
Decreasing performance - FCF yield.
Vericel Corporation has a free cash flow yield of 1.05%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Increasing performance - Healthy earnings growth.
Vericel Corporation's yearly earnings has increased 59.41% since last year from $10.36M to $16.52M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Vericel Corporation's yearly revenue has increased 16.45% since last year from $237.22M to $276.26M, signaling increasing performance
Decreasing performance - ROIC.
ROIC 3.35% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Vericel Corporation's 3-year revenue CAGR of 18.90% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Vericel Corporation had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Vericel Corporation had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Vericel Corporation is overvalued relative to its fair value price of 8.67 based on Discounted Cash Flow model
Overvalued - Earnings yield.
Vericel Corporation has an earnings yield of 0.92%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings
Overvalued - EBITDA valuation.
Vericel Corporation is overvalued relative to its fair value price of 4.20 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Vericel Corporation has an EV/EBITDA ratio of 77.64x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings
Undervalued - PEG ratio value.
Vericel Corporation has a PEG-ratio under 1 which is considered undervalued
Overvalued - P/B ratio.
Vericel Corporation has a price-to-book ratio of 6.57x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Overvalued - P/S ratio.
Vericel Corporation has a price-to-sales ratio of 8.01x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
6.41%
Return on equity
ROIC: 3.35%
Valuation History
109.6X
Price to Earnings
EV/EBITDA: 67.7X
Cash flow
Profit margin
41.01%
(FY vs FY)
Cash flow Y/Y
10.61%
(FY vs FY)
Base valuations use default assumptions. Customize in the Valuator.